Research Article| Volume 20, ISSUE 11, P1161-1166, November 1985

Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers

      This paper is only available as a PDF. To read, Please Download here.


      A clinical trial was undertaken to determine the role of dopaminergic and noradrenergic blockers in the maintenance treatment of remitted schizophrenics. One hundred and six remitted schizophrenic outpatients were treated with one of nine treatments, viz., thioridazine 25 mg or 75 mg, pimozide 2 mg or 6 mg, and their respective combinations, for 1 year in a double-blind controlled study employing a randomized design. The data from a previous study were utilized as a retrospective placebo group. Pimozide prolonged the number of symptom-free days in a dose-dependent manner and did so more markedly than thioridazine. Combined administration of pimozide and thioridazine prolonged the number of symptom-free days to a greater extent than their single administration. However, an inverted U-shaped dose-response curve was obtained with the combined administration of these agents. These data suggest that both the dopaminergic and noradrenergic blocking action of neuroleptics are important in preventing relapse in remitted schizophrenics.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Psychiatric Association
        3rd ed. Diagnostic and Statistical Manual of Mental Disorders. APA, Washington, DC1980: 181
        • Andén N.-E.
        • Butcher S.G.
        • Corrodi H.
        • Fuxe K.
        • Ungerstedt U.
        Receptor activity and turnover of dopamine and noradrenaline after neuroleptics.
        Eur J Pharmacol. 1970; 11: 303-314
        • Cheung H.K.
        Schizophrenics fully remitted on neuroleptics for 3–5 years—To stop or continue drugs?.
        Br J Psychiatry. 1981; 138: 490-494
        • Engelhart D.M.
        • Rosen B.
        • Freedman N.
        • Margolis R.
        Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization—A reevaluation.
        Arch Gen Psychiatry. 1967; 16: 98-101
        • Hirsh S.R.
        • Gaind R.
        • Rhode P.D.
        • Stevens B.C.
        • Wing J.K.
        Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial.
        Br Med J. 1973; 1: 633-637
        • Kane J.M.
        • Rifkin A.
        • Woerner M.
        • Reardon G.
        • Sarantakos S.
        • Schiebel D.
        • Ramos-Lorenzi J.
        Low-dose neuroleptic treatment of outpatient schizophrenics.
        Arch Gen Psychiatry. 1983; 40: 893-896
        • Leff J.P.
        • Wing J.K.
        Trial of maintenance therapy in schizophrenia.
        Br Med J. 1971; 3: 559-604
        • Lehmann H.E.
        • Wilson W.H.
        • Deutsch M.
        Minimal maintenance medication: Effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients.
        Compr Psychiatry. 1983; 24: 293-303
        • Meltzer H.Y.
        • Busch D.A.
        • Fang V.S.
        Effect of neuroleptics on serum prolactin levels in relation to clinical response and neuroleptic blood levels.
        in: Usden E. Clinical Pharmacology in Psychiatry. Elsevier, New York1981: 251
        • Miemegeers C.J.E.
        Quelques aspects pharmacologiques des neuroleptiques.
        Encephale. 1981; 7: 215-224
        • Nishikawa T.
        • Tsuda A.
        • Tanaka M.
        • Koga I.
        • Uchida Y.
        Prophylatic effect of neuroleptics in symptom-free schizophrenics.
        Psychopharmacology. 1982; 77: 301-304
        • Nishikawa T.
        • Tsuda A.
        • Tanaka M.
        • Hoaki Y.
        • Koga I.
        • Uchida Y.
        Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine.
        Psychopharmacology. 1984; 82: 153-156
        • Rubin R.T.
        • Hays S.E.
        The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations.
        Psychoneuroendocrinology. 1980; 5: 121-137
        • Troshinsky C.H.
        • Aaronson H.G.
        • Stone R.K.
        Maintenance phenothiazines in aftercare of schizophrenic patients.
        PA Psychiatr Q. 1962; 2: 11-15
        • Uchida Y.
        • Tsuda A.
        • Koga I.
        • Nishikawa T.
        A trial on follow-up in outpatients with psychosis using the computer system—Analysis of social adjustment levels and regularity of consultation and/or prescription.
        Seishin Igaku. 1983; 25: 477-484
        • Van Praag N.M.
        • Korf J.
        Biochemical research into psychosis.
        Acta Psychiatr Scand. 1975; 51: 268-284